Bamboo Therapeutics, Inc.

5 articles about Bamboo Therapeutics, Inc.

• 

  Pfizer Terminates Two DMD Studies Following Data Review

  8/30/2018

  Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
• 

  Biotech Companies Continue to Shake Up Leadership with New Appointments

  5/8/2018

  There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.

• CureDuchenne's Early Stage Investment In Bamboo Therapeutics Accelerates Gene Therapy For Duchenne, Bamboo Acquired By Pfizer

  8/1/2016

• Bamboo Therapeutics And CureDuchenne To Host A Webinar On Developing Gene Therapy For Duchenne Muscular Dystrophy On June 13, 2016

  6/2/2016

• Gene Therapy Company Bamboo Therapeutics Raises $49.5 Million in Apparent Series A Financing Round

  2/15/2016